Welcome to our dedicated page for Avadel Pharmaceu SEC filings (Ticker: AVDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avadel Pharmaceuticals plc (Nasdaq: AVDL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. Avadel is an Ireland-incorporated biopharmaceutical company focused on sleep-related disorders, and its filings provide detailed information on its commercial product LUMRYZ, clinical programs, licensing arrangements and corporate transactions.
Investors can review Avadel’s Form 10-K annual reports and Form 10-Q quarterly reports for narrative and quantitative discussions of LUMRYZ net product revenue, patient uptake, research and development spending, and risk factors related to narcolepsy, idiopathic hypersomnia and broader business operations. Current reports on Form 8-K highlight material events such as the Transaction Agreement and subsequent amendment with Alkermes plc, the proposed court-sanctioned scheme of arrangement under Irish law, settlement and license agreements with Jazz Pharmaceuticals, and the exclusive global license for valiloxybate from XWPharma.
These filings also document key clinical and regulatory milestones, including the FDA approvals that made LUMRYZ the first and only once-at-bedtime oxybate for extended-release oral suspension for cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy, Orphan Drug Exclusivity grants, and the design and status of Phase 3 studies such as REST-ON and REVITALYZ. Transaction-related disclosures describe the structure, consideration and conditions of the proposed acquisition by Alkermes and the evaluation of alternative proposals under the Irish Takeover Rules.
On Stock Titan, each new AVDL filing from EDGAR is surfaced in real time and paired with AI-powered summaries that explain the main points in clear language. Users can quickly see which filings involve LUMRYZ clinical data, royalty and license agreements, or the Alkermes acquisition terms, and can drill down into the full text for deeper analysis. Insider ownership and compensation details, when disclosed in proxy materials and related documents, are also accessible through the SEC filings stream, helping investors build a comprehensive view of governance and incentives at Avadel.
The Vanguard Group has filed a Schedule 13G disclosing a 5,564,259-share beneficial ownership position in Avadel Pharmaceuticals plc (AVDL), representing 5.74 % of the outstanding common stock as of 30 June 2025. The position is being reported on a passive basis under Rule 13d-1(b) and classified as an investment adviser (IA).
Voting rights are limited: Vanguard reports 0 shares with sole voting power and 107,614 shares with shared voting power. Dispositive authority is larger, with 5,361,014 shares under sole dispositive power and 203,245 shares under shared dispositive power, indicating the firm can direct disposition of virtually the entire stake while exercising minimal influence over corporate governance.
The filing, signed by Head of Global Fund Administration Ashley Grim on 29 July 2025, confirms that the shares were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.
Avadel Pharmaceuticals (Nasdaq: AVDL) filed an 8-K disclosing a decisive legal outcome.
On June 27 2025, the U.S. Court of Appeals for the D.C. Circuit issued a unanimous ruling affirming the District Court’s October 30 2024 judgment that upheld the FDA’s approval of LUMRYZ. The appeal was brought by Jazz Pharmaceuticals, which had alleged the approval violated the Administrative Procedure Act. With the appeal dismissed, LUMRYZ’s approval stands, eliminating a significant regulatory and litigation overhang.
No further conditions, penalties, or operational changes were reported.